Tianjin Pharmaceutical Holdings, Ltd.

Tianjin Pharmaceutical Holdings Co., Ltd. (TPH) is a state-owned limited liability company that integrates scientific research, industry and commerce into one entity with the status of an independent corporate capacity, and one of the 520 large-scale enterprise groups in China. It’s authorized to handle state-owned assets.

TPH has 81 industrial and commercial enterprises and 316 commercial retail networks. The business covers bulk chemicals and finished pharmaceutical preparations, bioengineering products, Chinese patent medicines, healthcare products, medical devices and pharmaceutical machinery, totally six manufacturing industries, as well as wholesale and retail. The products with advanced technology and high added value enjoy high superiority in international market.

The countrywide commercial enterprises of TPH handle over ten thousand products such as Chinese patent medicines, chemical products, per-manufacturing traditional Chinese medicines and medical devices, etc.

TPH total assets amount to RMB 10.4 billion and net assets amount to RMB 4.8 billion. The sale in 2004 was RMB 12 billion, and profit RMB 524 million.

It ranked the first Chinese enterprise in the world 500 most competitive pharmaceutical enterprises, and 30th in the most competitive enterprises group credited by the State in 2002. TPH has been in the first 500 most competitive enterprise for the consecutive two years of 2002 and 2003, and ranked 3rd in the 18 pharmaceutical enterprises in the 500 most competitive enterprises in 2003.

TPH focus on developing bio-technique, modern medicine and modernization of traditional Chinese medicine. We’re now manufacturing and developing the areas such as antipyretic and analgesic products, anti-infection drugs, cardio-cerebral vascular products, vitamin, anti-cancer drugs, etc. We also welcome collaboration on products with remarkable effect on respiratory system, central nervous system, digestive system, parasite, etc., as well as new dosage forms and products like sustained-release products, target medicines, trans-dermal products, etc.

From 2003, TPH took the growing strategy to make the most competitive large group enterprise in pharmaceutical line in China and contribute to human health.


	Tianjin Pharmaceutical Holdings, Ltd. Tianjin Pharmaceutical Holdings Co., Ltd. (TPH) is a state-owned limited liability company that integrates scientific research, industry and commerce into one entity with the status of an independent corporate capacity, and one of the 520 large-scale enterprise groups in China. It’s authorized to handle state-owned assets. TPH has 81 industrial and commercial enterprises and 316 commercial retail networks. The business covers bulk chemicals and finished pharmaceutical preparations, bioengineering products, Chinese patent medicines, healthcare products, medical devices and pharmaceutical machinery, totally six manufacturing industries, as well as wholesale and retail. The products with advanced technology and high added value enjoy high superiority in international market. The countrywide commercial enterprises of TPH handle over ten thousand products such as Chinese patent medicines, chemical products, per-manufacturing traditional Chinese medicines and medical devices, etc. TPH total assets amount to RMB 10.4 billion and net assets amount to RMB 4.8 billion. The sale in 2004 was RMB 12 billion, and profit RMB 524 million. It ranked the first Chinese enterprise in the world 500 most competitive pharmaceutical enterprises, and 30th in the most competitive enterprises group credited by the State in 2002. TPH has been in the first 500 most competitive enterprise for the consecutive two years of 2002 and 2003, and ranked 3rd in the 18 pharmaceutical enterprises in the 500 most competitive enterprises in 2003. TPH focus on developing bio-technique, modern medicine and modernization of traditional Chinese medicine. We’re now manufacturing and developing the areas such as antipyretic and analgesic products, anti-infection drugs, cardio-cerebral vascular products, vitamin, anti-cancer drugs, etc. We also welcome collaboration on products with remarkable effect on respiratory system, central nervous system, digestive system, parasite, etc., as well as new dosage forms and products like sustained-release products, target medicines, trans-dermal products, etc. From 2003, TPH took the growing strategy to make the most competitive large group enterprise in pharmaceutical line in China and contribute to human health.